日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis

在 PIONEER 研究中,avapritinib 治疗惰性系统性肥大细胞增生症期间发生的过敏反应事件

Pongdee, Thanai; Castells, Mariana; Akin, Cem; Dybedal, Ingunn; Gotlib, Jason; Panse, Jens Peter; Alvarez-Twose, Ivan; Cabeza, Cristina Morales; Cerquozzi, Sonia; Vadas, Peter; Swarup, Vidushi; Vachhani, Pankit; Wortmann, Friederike; Yi, Cecilia Arana; Bidollari, Ilda; Newberry, Kate; Shaheen, Daniel; Hartmann, Karin

Assays to enhance metabolic phenotyping in the kidney.

用于增强肾脏代谢表型分析的检测方法

Hammoud Safaa, Kern Justin, Mukherjee Sandip, Lutkewitte Andrew J, Singh Prabhleen, Newberry Kate, Finck Brian N, Gewin Leslie S

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

阿伐替尼与瑞戈非尼治疗局部晚期不可切除或转移性胃肠道间质瘤:一项随机、开放标签的III期研究

Kang, Yoon-Koo; George, Suzanne; Jones, Robin L; Rutkowski, Piotr; Shen, Lin; Mir, Olivier; Patel, Shreyaskumar; Zhou, Yongjian; von Mehren, Margaret; Hohenberger, Peter; Villalobos, Victor; Brahmi, Mehdi; Tap, William D; Trent, Jonathan; Pantaleo, Maria A; Schöffski, Patrick; He, Kevin; Hew, Paggy; Newberry, Kate; Roche, Maria; Heinrich, Michael C; Bauer, Sebastian

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

五聚蛋白-3血浆水平与原发性骨髓纤维化患者的肿瘤负荷和总生存期相关

Veletic, Ivo; Manshouri, Taghi; Newberry, Kate J; Garnett, Jeannine; Verstovsek, Srdan; Estrov, Zeev

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

鲁索替尼停药后骨髓纤维化患者的克隆演变和预后

Newberry, Kate J; Patel, Keyur; Masarova, Lucia; Luthra, Rajyalakshmi; Manshouri, Taghi; Jabbour, Elias; Bose, Prithviraj; Daver, Naval; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

聚乙二醇干扰素α-2a治疗原发性血小板增多症或真性红细胞增多症患者:一项开放标签II期试验的事后分析,中位随访时间为83个月

Masarova, Lucia; Patel, Keyur P; Newberry, Kate J; Cortes, Jorge; Borthakur, Gautam; Konopleva, Marina; Estrov, Zeev; Kantarjian, Hagop; Verstovsek, Srdan

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

一种准确、简单的原发性骨髓纤维化患者预后模型,包含年龄、JAK2、CALR 和 MPL 突变状态

Rozovski, Uri; Verstovsek, Srdan; Manshouri, Taghi; Dembitz, Vilma; Bozinovic, Ksenija; Newberry, Kate; Zhang, Ying; Bove, Joseph E 4th; Pierce, Sherry; Kantarjian, Hagop; Estrov, Zeev

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

血小板分离术在骨髓增生性肿瘤合并血小板增多症的现代治疗中的作用:病例回顾

Boddu, Prajwal; Falchi, Lorenzo; Hosing, Chitra; Newberry, Kate; Bose, Prithviraj; Verstovsek, Srdan

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

原发性血小板增多症后和真性红细胞增多症后患者与原发性骨髓纤维化患者有所不同

Masarova, Lucia; Bose, Prithviraj; Daver, Naval; Pemmaraju, Naveen; Newberry, Kate J; Manshouri, Taghi; Cortes, Jorge; Kantarjian, Hagop M; Verstovsek, Srdan

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience

原发性血小板增多症和真性红细胞增多症患者的继发性实体瘤和淋巴瘤——单中心经验

Masarova, Lucia; Cherry, Mohamad; Newberry, Kate J; Estrov, Zeev; Cortes, Jorge E; Kantarjian, Hagop M; Verstovsek, Srdan